- Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
- Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
- Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
- Fulcrum Therapeutics to Participate in Upcoming May Conferences
- Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
- Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
More ▼
Key statistics
As of last trade Fulcrum Therapeutics Inc (FULC:NMQ) traded at 8.86, -35.33% below its 52-week high of 13.70, set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.57 |
---|---|
High | 9.14 |
Low | 8.57 |
Bid | 8.86 |
Offer | 8.88 |
Previous close | 8.60 |
Average volume | 834.71k |
---|---|
Shares outstanding | 62.15m |
Free float | 61.29m |
P/E (TTM) | -- |
Market cap | 534.52m USD |
EPS (TTM) | -1.61 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 20:42 BST.
More ▼